Research programme: T-cell therapies - Adaptimmune

Drug Profile

Research programme: T-cell therapies - Adaptimmune

Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; AFP SPEAR T-cell therapy; AFP TCR - Adaptimmune; AFP-targeted T-cell therapies; Allogenic T-cell therapies - Adaptimmune; Alpha fetoprotein-targeted T-cell therapies; Autologous genetically modified T-cells - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; MAGE-A4 SPEAR T-cell therapy; PRAME; Preferentially expressed antigen in melanoma

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Adaptimmune
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Hepatocellular carcinoma; Non-small cell lung cancer
  • Research Diabetes mellitus; Hepatitis C; Immunological disorders; Liver cancer

Most Recent Events

  • 09 Jan 2017 US FDA approves IND application for MAGE-A4 SPEAR T-cell therapy in Solid tumours (malignant)
  • 09 Jan 2017 Adaptimmune plans a phase I trial in Solid tumours
  • 20 Dec 2016 Adaptimmune Therapeutics and Bellicum Pharmaceuticals collaborate to evaluate, develop, and commercialise T-cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top